About me
Dusty Majumdar assumed the role of CEO at PredxBio in 2022, spearheading the company’s mission to lead the field of Spatial Biology through delving into the mechanism of action of cancer drugs and predicting patient outcomes with over 90% accuracy harnessing the power of AI-driven spatial biomarkers. Under his leadership, PredxBio is revolutionizing drug discovery and clinical development working with the Top 20 Pharmaceutical unlocking novel insights and improving patient outcomes.
Dusty Majumdar is an accomplished leader in precision healthcare with over 20 years of experience driving innovation in oncology, multi-omics, real-world evidence, and advanced diagnostic platforms. Prior to joining PredxBio as CEO, Dusty held strategic leadership and executive roles at IBM as the Chief Strategy and Marketing Officer, where he led C-suite-level initiatives in healthcare/life sciences, as well as at GE Healthcare (across modalities in Diagnostic Imaging), Exact Sciences, and 3M. He also served as a senior executive advisor to the American Society of Clinical Oncology (ASCO), contributing to the launch of the CancerLinq platform across academic and community hospitals.
A sought-after speaker and thought leader, Dusty has delivered plenary talks at prestigious forums such as The Global Economist Forum (War on Cancer), CodeX London (invited to the Top 50 Innovators' Forum), and MIT Sloan School (AI in Precision Medicine). His expertise has shaped global conversations on AI in healthcare, and his efforts have earned him numerous accolades, including the Heroes in Healthcare Award from VNA Boston.
Recognized as a global leader in life sciences, Dusty holds a Ph.D. from the University of Texas at Austin and a bachelor’s degree from the Indian Institute of Technology (IIT) Kharagpur. He has authored over 25 peer-reviewed scientific publications, holds 30+ patents, and continues to lead impactful advancements at the intersection of AI and healthcare/life sciences innovation.
About PredxBio:
PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts patient outcomes with over 90% accuracy. PredxBio's SpaceIQ Platform offers unprecedented insights into the intricate biology of cancer by going from biopsy images all the way to exposing the network biology (pathways) of cancer. PredxBio is redefining the future of cancer care with its explainable AI-driven spatial analytics. By transforming spatial data into actionable insights, PredxBio is setting new standards in biomarker discovery and precision therapeutics to impact over 25 million cancer patients worldwide.
